U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended June 30, 2004

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                  to
                                    -----------------   ---------------

                       Commission File No. 0-49655
                                           -------


                         LIPIDVIRO TECH, INC.
                         --------------------
     (Exact Name of Small Business Issuer as specified in its Charter)


            Nevada                                     87-0678927
            ------                                     ----------
  (State or Other Jurisdiction of                (I.R.S. Employer I.D. No.
incorporation or organization)


                        2120 South 700 East, #H183
                        Salt Lake City, Utah 84106
                        --------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (801) 583-9900
                                            --------------

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                                     N/A

     Check whether the Registrant filed all documents and reports required to
be filed by Section 12, 13, or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.  Yes    No

                   APPLICABLE ONLY TO CORPORATE ISSUERS

     State the number of shares outstanding of each of the Registrant's
classes of common equity, as of the latest practicable date:

                           June 30, 2004

              Common Voting Stock - 10,031,863 shares

Transitional Small Business Disclosure Format (Check one):  Yes X   No


ITEM 1 Financial Statements

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management and commence below,
together with related Notes.  In the opinion of management, the Financial
Statements fairly present the financial condition of the Registrant.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

        UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                            JUNE 30, 2004
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]




                              CONTENTS

                                                                 PAGE

     Unaudited Condensed Consolidated Balance
          Sheets, June 30, 2004 and December 31, 2003             2

     Unaudited Condensed Consolidated Statements of
          Operations, for the three and six months ended
          June 30, 2004 and from inception on May 6,
          2003 through June 30, 2003 and 2004                     3

     Unaudited Condensed Consolidated Statements of
          Cash Flows, for the six months ended
          June 30, 2004 and from inception on May 6,
          2003 through June 30, 2003 and 2004                     4

     Notes to Unaudited Condensed Consolidated
          Financial Statements                               5 - 12
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

           UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

                               ASSETS
                                                       June 30,  December 31,
                                                         2004        2003
                                                   ___________  ___________
CURRENT ASSETS:
  Cash                                              $    3,723  $     3,702
  Prepaid expense                                        2,500        3,919
                                                   ___________  ___________
        Total Current Assets                             6,223        7,621
                                                   ___________  ___________

PROPERTY AND EQUIPMENT, net                              2,800        2,118
                                                   ___________  ___________

OTHER ASSETS:
  Definite-life intangible assets, net                   5,826            -
  Goodwill                                             290,317      269,006
                                                   ___________  ___________
        Total Other Assets                             296,143      269,006
                                                   ___________  ___________

                                                   $   305,166  $   278,745
                                                   ___________  ___________

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                                 $    52,501  $    26,387
  Shareholder advances                                 116,500       65,000
                                                   ___________  ___________
        Total Current Liabilities                      169,001       91,387
                                                   ___________  ___________

STOCKHOLDERS' EQUITY [Restated]:
  Common stock, $.001 par value,
   150,000,000 shares authorized,
   10,031,862 and 9,818,750 shares
   issued and outstanding, respectively                 10,032        9,819
  Capital in excess of par value                       344,352      323,254
  Deficit accumulated during the
   development stage                                  (218,219)    (145,715)
                                                   ___________  ___________
        Total Stockholders' Equity                     136,165      187,358
                                                   ___________  ___________

                                                   $   305,166  $   278,745
                                                   ___________  ___________

Note: The balance sheet at December 31, 2003 was taken from the audited
financial statements at that date and condensed.

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


                                                             From Inception
                               For the    For the            on May 6, 2003
                            Three Months  Six Months        Through June 30,
                                Ended       Ended       _____________________
                           June 30, 2004  June 30, 2004    2003       2004
                           __________________________________________________
REVENUE                       $           -  $        - $        -   $      -

EXPENSES:
  General and administrative         12,039      24,136      5,079    104,293
  Research and development           23,575      48,368     46,215    113,926
                                ___________ ___________ __________ __________
      Total Expenses                 35,614      72,504     51,294    218,219
                                ___________ ___________ __________ __________

LOSS BEFORE INCOME
  TAXES                            (35,614)    (72,504)   (51,294)   (218,219)

CURRENT TAX EXPENSE
  (BENEFIT)                               -           -          -          -

DEFERRED TAX EXPENSE
  (BENEFIT)                               -           -          -          -
                                ___________ ___________ __________ __________

NET LOSS                        $   (35,614)$   (72,504)$  (51,294)$ (218,219)
                                ___________ ___________ __________ __________

LOSS PER COMMON SHARE           $      (.00)$      (.00)$     (.01)$     (.02)
                                ___________ ___________ __________ __________


The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                           From Inception
                                             For the       on May 6, 2003
                                           Six Months      Through June 30,
                                              Ended      ____________________
                                         June 30, 2004      2003       2004
                                         _____________   __________ _________
Cash Flows from Operating Activities:
 Net loss                                $     (72,504)  $  (51,294)$(218,219)
 Adjustments to reconcile net loss to
  net cash used by operating activities:
  Depreciation expense                             278            -       463
  Non-cash expenses paid by issuance of
  common stock                                       -          750       750
  Non-cash services paid by issuance of
  common stock                                       -          113       113
  Changes in assets and liabilities:
   Decrease (increase) in prepaid expense        1,419       (3,050)   (2,500)
   Increase in accounts payable                 26,114          174    52,501
   Increase in accrued expenses                      -           15         -
                                         _____________   __________ _________
        Net Cash (Used) by Operating
        Activities                             (44,693)     (53,292) (166,892)
                                         _____________   __________ _________
Cash Flows from Investing Activities:
 Payments for property and equipment              (960)           -    (3,263)
 Payments for definite-life intangible assets   (5,826)           -    (5,826)
 Payments for goodwill                               -     (269,006) (269,006)
                                         _____________   __________ _________
        Net Cash (Used) by Investing
        Activities                              (6,786)    (269,006) (278,095)
                                         _____________   __________ _________
Cash Flows from Financing Activities:
 Proceeds from bank overdrafts                       -            6         -
 Proceeds from shareholder advances             51,500            -   116,500
 Proceeds from issuance of common stock              -      332,210   293,700
 Proceeds from sale of warrants                      -            -    38,510
                                         _____________   __________ _________
        Net Cash Provided by Financing
        Activities                              51,500      332,216   448,710
                                         _____________   __________ _________
Net Increase (Decrease) in Cash                     21        9,918     3,723

Cash at Beginning of Period                      3,702            -         -
                                         _____________   __________ _________
Cash at End of Period                    $       3,723   $    9,918 $   3,723
                                         _____________   __________ _________
Supplemental Disclosures of Cash Flow Information:
 Cash paid during the period for:
   Interest                              $           -   $        - $       -
   Income taxes                          $           -   $        - $       -

Supplemental Schedule of Non-cash Investing and Financing Activities:
 For the period from inception on May 6, 2003 through June 30, 2004:
  In January 2004, the Company issued 213,112 shares of common stock as part
  of a downstream merger [See Note 2].

  In June 2003, the Company issued 3,750 shares of common stock for services
  rendered valued at $113.
  In May 2003, the Company issued 25,000 shares of common stock as repayment
  of organization costs of $750.

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

     Organization - LipidViro Tech, Inc. ("Parent") was organized under the
     laws of the State of California on October 19, 1954 as Anticline
     Uranium, Inc.  In October 2001, Parent changed its domicile from
     California to Nevada by merging with and into a wholly owned subsidiary
     with the same name and the Nevada entity being the surviving entity.  In
     January 2004, Parent changed its name to LipidViro Tech, Inc.  On June
     24, 2003, Subsidiary acquired 95.9% of the outstanding stock of Parent
     pursuant to a Share Purchase Agreement.  The agreement called for
     Subsidiary to pay $65,718 to the former shareholders of Parent for
     5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
     owned subsidiary of Subsidiary [See Note 3].  On January 14, 2004,
     Parent issued 9,818,750 shares of its common stock for all 9,818,750
     outstanding shares of Subsidiary's common stock wherein Subsidiary
     became a wholly owned subsidiary of Parent in a transaction which has
     been accounted for as a downstream merger [See Note 2].  Accordingly,
     the equity transactions have been restated to reflect the
     recapitalization of Subsidiary and the operations of Parent prior to
     June 24, 2003 have been eliminated.  The financial statements reflect
     the operations of Subsidiary from its inception.

     Lipidviro Tech Inc. ("Subsidiary") was organized under the laws of the
     State of Utah on May 6, 2003.

     LipidViro Tech, Inc. and Subsidiary ("the Company") plans to research and
     market substances and compounds for antiviral and antibacterial purposes.
     The Company has not generated any revenues from their planned principal
     operations and is considered a development stage company as defined in
     Statement of Financial Accounting Standards No. 7.  The Company has, at
     the present time, not paid any dividends and any dividends that may be
     paid in the future will depend upon the financial requirements of the
     Company and other relevant factors.

     Condensed Financial Statements - The accompanying financial statements
     have been prepared by the Company without audit.  In the opinion of
     management, all adjustments (which include only normal recurring
     adjustments) necessary to present fairly the financial position, results
     of operations and cash flows at June 30, 2004 and for the periods then
     ended have been made.

     Certain information and footnote disclosures normally included in
     financial statements prepared in accordance with generally accepted
     accounting principles in the United States of America have been condensed
     or omitted.  It is suggested that these condensed financial statements be
     read in conjunction with the financial statements and notes thereto
     included in the Company's December 31, 2003 audited financial statements.
     The results of operations for the periods ended June 30, 2004 are not
     necessarily indicative of the operating results for the full year.

     Consolidation - The consolidated financial statements include the
     accounts of Parent and Parent's wholly owned Subsidiary.  All significant
     intercompany transactions have been eliminated in consolidation.

     Cash and Cash Equivalents - The Company considers all highly liquid debt
     investments purchased with a maturity of three months or less to be cash
     equivalents.

<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

     Property and Equipment - Property and equipment are stated at cost.
     Expenditures for major renewals and betterments that extend the useful
     lives of property and equipment are capitalized upon being placed in
     service.  Expenditures for maintenance and repairs are charged to expense
     as incurred.  Depreciation is computed using the straight-line method
     over the estimated useful lives of the assets of five years.  In
     accordance with Statement of Financial Accounting Standards No. 144,
     "Accounting for the Impairment or Disposal of Long-Lived Assets", the
     Company periodically reviews their property and equipment for impairment.

     Website Costs - The Company has adopted the provisions of Emerging
     Issues Task Force 00-2, "Accounting for Web Site Development Costs."
     Costs incurred in the planning stage of a website are expensed as
     research and development while costs incurred in the development stage
     are capitalized and amortized over the life of the asset, estimated to
     be five years.  As of June 30, 2004, the Company has capitalized a total
     of $2,830 of website costs which are included in property and equipment.
     The Company did not incur any planning costs and did not record any
     research and development costs for the six months ended June 30, 2004.

     Intangible Assets - The Company accounts for their intangible assets in
     accordance with Statement of Financial Accounting Standards No. 142,
     "Goodwill and Other Intangible Assets".  SFAS No. 142 establishes three
     classifications for intangible assets including definite-life intangible
     assets, indefinite-life intangible assets and goodwill and requires
     different accounting treatment and disclosures for each classification.
     In accordance with SFAS No. 142, the Company periodically reviews their
     intangible assets for impairment.  No impairment was recorded during the
     six months ended June 30, 2004.

     Research and Development - Research and development costs are expensed
     as incurred.  The Company expensed $48,368 in research and development
     costs during the six months ended June 30, 2004.

     Income Taxes - The Company accounts for income taxes in accordance with
     Statement of Financial Accounting Standards No. 109 "Accounting for
     Income Taxes" [See Note 8].

     Minority Interest - From June 24, 2003 through January 14, 2004,
     Subsidiary owned 95.9% of Parent.  The net loss of Parent applicable to
     the non-controlling minority interest was not allocated to the minority
     interests as there was no obligation of the non-controlling minority
     interests to share in such losses.  On January 14, 2004, Subsidiary
     acquired the minority interest in a downstream merger [See Note 2].

     Loss Per Share - The computation of loss per share is based on the
     weighted average number of shares outstanding during the period
     presented in accordance with Statement of Financial Accounting Standards
     No. 128, "Earnings Per Share" [See Note 11].
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

     Accounting Estimates - The preparation of financial statements in
     conformity with generally accepted accounting principles in the United
     States of America requires management to make estimates and assumptions
     that affect the reported amounts of assets and liabilities, the
     disclosures of contingent assets and liabilities at the date of the
     financial statements, and the reported amount of revenues and expenses
     during the reported period.  Actual results could differ from those
     estimated.

     Recently Enacted Accounting Standards - Statement of Financial
     Accounting Standards ("SFAS") No. 149, "Amendment of Statement 133 on
     Derivative Instruments and Hedging Activities", and SFAS No. 150,
     "Accounting for Certain Financial Instruments with Characteristics of
     both Liabilities and Equity", were recently issued.  SFAS No. 149 and
     150 have no current applicability to the Company or their effect on the
     financial statements would not have been significant.

     Reclassification - The financial statements for periods prior to June
     30, 2004 have been reclassified to conform to the headings and
     classifications used in the June 30, 2004 financial statements.

     Restatement - The financial statements have been restated for all
     periods presented to reflect the recapitalization of Subsidiary [See
     Note 2] and to reflect a 1-for-100 reverse stock split that Parent
     effected on October 4, 2001 and a 4-for-1 forward stock split that
     Parent effected on December 31, 2001 [See Note 7].

NOTE 2 - DOWNSTREAM MERGER

     On January 14, 2004, Subsidiary acquired the minority interests in
     Parent and Subsidiary was reorganized as a subsidiary of Parent in a
     transaction in which Parent issued 9,818,750 shares of its common stock
     in exchange for all 9,818,750 outstanding shares of Subsidiary's common
     stock.  Accordingly, the equity transactions have been restated to
     reflect the recapitalization of Subsidiary.  The Company recorded
     goodwill of $21,311 as a result of the downstream merger.  The financial
     statements reflect the operations of Subsidiary from its inception.  As
     part of the downstream merger, Parent issued 1,915,000 Class A warrants
     and 1,915,000 Class B warrants to replace similar warrants of
     Subsidiary.  Parent also cancelled 5,000,000 shares of its common stock
     which had previously been owned by Subsidiary.

<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 - ACQUISITION OF 95.9% OF LIPIDVIRO TECH, INC.

     On June 24, 2003, Subsidiary acquired 95.9% of the outstanding stock of
     Parent pursuant to a Share Purchase Agreement.  The agreement called for
     Subsidiary to pay $65,718 to the former shareholders of Parent for
     5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
     owned subsidiary of Subsidiary.  The agreement also called for
     Subsidiary to advance an additional $203,282 to pay costs associated
     with the acquisition and to reduce the liabilities of Parent.  The
     acquisition closed June 24, 2003 and has been accounted for as a
     purchase of Parent.  The Company recorded goodwill of $269,006 as a
     result of the acquisition.  The financial statements reflect the
     operations of Parent from June 24, 2003.

NOTE 4 - PROPERTY AND EQUIPMENT

     Property and equipment consisted of the following at:

                                        June 30,  December 31,
                                          2004       2003
                                   ___________    ___________
     Office equipment              $       433    $       433
     Website                             2,830          1,870
                                   ___________    ___________
                                         3,263          2,303

     Less: accumulated depreciation       (463)          (185)
                                   ___________    ___________
     Net property and equipment    $     2,800    $     2,118
                                   ___________    ___________

     Depreciation expense for the six months ended June 30, 2004 was $115.

NOTE 5 - DEFINITE-LIFE INTANGIBLE ASSETS

     Definite-life intangible assets consist of the following at:

                                                   June 30,  December 31,
                                                    2004         2003
                                               ___________    ___________
          Patent applications in process       $     5,826    $         -

          Less: Accumulated amortization                 -              -
                                               ___________    ___________
          Net Definite-life Intangible Assets  $     5,826    $         -
                                               ___________    ___________

     The Company's definite-life intangible assets are amortized, upon being
     placed in service, over the estimated useful lives of the assets of 20
     years with no residual value.  Amortization expense for the six months
     ended June 30, 2004 was $0.  The Company estimates that their
     amortization expense for each of the next five years will be
     approximately $200 per year.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - GOODWILL

          The Company has no indefinite-life intangible assets.  The following
          is a summary of the transactions affecting the Company's goodwill.

                                                          From Inception
                                For the     For the       on May 6, 2003
                             Three Months  Six Months     Through June 30,
                                 Ended       Ended      _____________________
                            June 30, 2004 June 30, 2004    2003       2004
                            _________________________________________________
  Goodwill at beginning of
    period                  $   290,317  $    269,006   $       -   $       -

  Goodwill from the
    acquisition of 95.9%
    of Parent                         -             -     269,006     269,006

  Goodwill from the
    acquisition of the
    minority interests in
    Parent                            -        21,311           -      21,311
                            ___________  ____________   _________   _________

  Goodwill at end of period $   290,317  $    290,317   $ 269,006   $ 290,317
                            ___________  ____________   _________   _________

NOTE 7 - CAPITAL STOCK

     Common Stock - The Company has authorized 150,000,000 shares of common
     stock with a par value of $.001.

     In January 2004, the Company issued 213,112 shares of their previously
     authorized but unissued common stock to the former shareholders of
     Subsidiary as part of a downstream merger [See Note 2].

     In June 2003, the Company issued 3,750 shares of their previously
     authorized but unissued common stock to an officer of the Company for
     services rendered valued at $113, or $.03 per share.

     In June 2003, the Company issued 7,875,000 shares of their previously
     authorized but unissued common stock for cash of $236,250, or .03 per
     share.

     In May 2003, the Company issued 1,915,000 units.  Each unit consisted of
     one share of the Company's previously authorized but unissued common
     stock, one Class A warrant and one Class B warrant.  The units were
     issued for cash of $95,960, or approximately $.05 per unit.

     In May 2003, in connection with their organization, the Company issued
     25,000 shares of their previously authorized but unissued common stock
     to an officer of the Company as repayment of organization costs of $750,
     or $.03 per share.

<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK [Continued]

     Stock Splits - On December 31, 2001, Parent effected a 4-for-1 forward
     stock split.  On October 4, 2001, Parent effected a 1-for-100 reverse
     stock split.  The financial statements for all periods presented have
     been restated to reflect these stock splits.

     Class A Warrants - In May 2003, the Company issued 1,915,000 Class A
     Warrants for cash of $19,255, or approximately $.01 per warrant, as part
     of a private placement offering.  The warrants vested immediately and
     are exercisable at $5.00 per share.  The warrants were originally
     exercisable for two years.  In August 2003, the Company changed the
     exercise period so the warrants are only exercisable during June 2006.
     At June 30, 2004, none of these warrants had been exercised, forfeited
     or cancelled.

     Class B Warrants - In May 2003, the Company issued 1,915,000 Class B
     Warrants for cash of $19,255, or approximately $.01 per warrant, as part
     of a private placement offering.  The warrants vested immediately and
     are exercisable at $10.00 per share.  The warrants were originally
     exercisable for two years.  In August 2003, the Company changed the
     exercise period so the warrants are only exercisable during June 2006.
     At June 30, 2004, none of these warrants had been exercised, forfeited
     or cancelled.

     Stock Option Plan - In March 2003, the Board of Directors of Parent
     approved and adopted the "2003 Stock Option/Stock Issuance Plan" ("the
     Plan") with a maximum of 1,500,000 shares of common stock reserved for
     issuance under the Plan.  The Plan provides for both the direct award of
     shares and for the grant of options to purchase shares.  The Board of
     Directors has authorized options to purchase 500,000 common shares to be
     granted at a purchase price of $0.01 per share, but to date the Company
     has not granted any options to their employees, officers or directors.
     Under the Plan, the Board of Directors shall determine which eligible
     persons are to receive Incentive Options, Non-Statutory grants or stock
     issuances.  The Board of Directors also sets the exercise price for
     options granted.  The option terms are not to exceed ten years from the
     option grant date.  At June 30, 2004, total awards available to be
     granted from the Plan amounted to 1,500,000.

NOTE 8 - INCOME TAXES

     The Company accounts for income taxes in accordance with Statement of
     Financial Accounting Standards No. 109 "Accounting for Income Taxes".
     SFAS No. 109 requires the Company to provide a net deferred tax
     asset/liability equal to the expected future tax benefit/expense of
     temporary reporting differences between book and tax accounting methods
     and any available operating loss or tax credit carryforwards.  The
     Company has available at June 30, 2004 unused operating loss
     carryforwards of approximately $279,000 which may be applied against
     future taxable income and which expire in various years through 2024.
     Due to substantial changes in the Company's ownership, there will be an
     annual limitation on the amount of net operating loss carryforwards
     which can be utilized.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 - INCOME TAXES [Continued]

     The amount of and ultimate realization of the benefits from the
     operating loss carryforwards for income tax purposes is dependent, in
     part, upon the tax laws in effect, the future earnings of the Company,
     and other future events, the effects of which cannot be determined.
     Because of the uncertainty surrounding the realization of the deferred
     tax assets, the Company has established a valuation allowance equal to
     the tax effect of the loss carryforwards, therefore, no deferred tax
     asset has been recognized.  The net deferred tax assets, which consist
     of difference in book and tax basis of fixed assets and net operating
     losses, are approximately $54,800 and $38,400 as of June 30, 2004 and
     December 31, 2003, respectively, with an offsetting valuation allowance
     of the same amount, resulting in a change in the valuation allowance of
     approximately $16,400 during the six months ended June 30, 2004.

NOTE 9 - RELATED PARTY TRANSACTIONS

     Management Compensation - The Company has not paid any cash compensation
     to any officer or director of the Company.  However, in June 2003, the
     Company issued 3,750 shares of common stock to an officer of the Company
     for services rendered valued at $113 [See Note 7].

     Office Space - The Company has not had a need to rent office space.  A
     shareholder (former officer) of the Company is allowing the Company to
     use her mailing address, as needed, at no expense to the Company.

     Stock Issuance - In May 2003, in connection with their organization, the
     Company issued 25,000 shares of their previously authorized but unissued
     common stock to an officer of the Company as repayment of organization
     costs of $750, or $.03 per share.

     Shareholder Advances - During the six months ended June 30, 2004, a
     shareholder of the Company advanced $51,500 to the Company.  At June 30,
     2004, the Company owes a total of $116,500 to the shareholder.  The
     advances bear no interest and are due December 31, 2004.

NOTE 10 - GOING CONCERN

     The accompanying financial statements have been prepared in conformity
     with generally accepted accounting principles in the United States of
     America, which contemplate continuation of the Company as a going
     concern.  However, the Company was only recently formed and has not yet
     been successful in establishing profitable operations.  Further, the
     Company has current liabilities in excess of current assets.  These
     factors raise substantial doubt about the ability of the Company to
     continue as a going concern.  In this regard, management is proposing to
     raise any necessary additional funds not provided by operations through
     loans or through additional sales of their common stock.  There is no
     assurance that the Company will be successful in raising this additional
     capital or in achieving profitable operations.  The financial statements
     do not include any adjustments that might result from the outcome of
     these uncertainties.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 - LOSS PER SHARE

  The following data shows the amounts used in computing loss per share:

                                                          From Inception
                                For the     For the       on May 6, 2003
                             Three Months  Six Months     Through June 30,
                                 Ended       Ended      _____________________
                            June 30, 2004 June 30, 2004    2003       2004
                            _________________________________________________
     Loss from continuing
     operations available
     to common shareholders
     (numerator)            $   (35,614)  $ (72,504)    $ (51,294) $ (218,219)
                            ___________   _________     _________  __________
     Weighted average number
     of common shares
     outstanding used in loss
     per share for the period
     (denominator)           10,031,862  10,015,469     3,430,938   9,175,491
                            ___________  __________     _________  __________

     At June 30, 2004, the Company had 1,915,000 Class A warrants and
     1,915,000 Class B warrants outstanding which were not used in the
     computation of dilutive loss per share because their effect would be
     anti-dilutive.  Dilutive loss per share was not presented, as the
     Company had no common stock equivalent shares for all periods presented
     that would effect the computation of diluted loss per share.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

     Agreements - In October 2003, the Company signed one-year agreements for
     the use of a research facility and staff to conduct research on behalf
     of the Company and to have a researcher coordinate the activities.  The
     Company will pay up to $76,325 for supplies, facilities, a laboratory
     technician and coordination efforts.

     Possible Claims Related to Previously Leased Mining Property - In August
     2001, Parent obtained 96.5% of the rights to certain mining claims in
     the Tintic Mining District of Juab County, Utah under the terms of a 5-
     year Mining Lease.  Under the terms of the lease, Parent was obligated
     to spend $15,000 over the term of the lease for exploration, mining,
     development or similar costs for the benefit of the property subject to
     the lease.  Parent was also obligated to pay a 3.5% net smelter royalty
     on all mineral-bearing ores sold.  The lease also gave a credit to
     Parent for the first $30,000 of net smelter royalties.  The lessor also
     agreed to indemnify and hold Parent harmless from any Environmental
     Protection Agency claim or claims by a similar state agency based solely
     on past mining contaminations or other environmental violations or
     damage.  In June 2003, Parent paid $3,459 to cancel the Mining Lease.
     The Company's management believes that the Company would not be
     responsible for any future claims against the property which Parent
     previously leased, but the possibility exists that claims may arise
     against the property and the Company may be named in such claims based
     on the previous leasing arrangements.  The Company's management believes
     that the Company would be successful in defending against any such
     claims that may arise.  No accrual for possible losses or settlements
     has been recorded in the accompanying financial statements.
<PAGE>
ITEM 2 Management Discussion and Analysis or Plan of Operation

Plan of Reorganization.
-----------------------

          On June 24, 2003, a Share Purchase Agreement (the Agreement") was
executed by and between North Beck Joint Venture, LLC, a Utah limited
liability company ("North Beck"), that was the owner of approximately 96% of
the outstanding voting securities of the Registrant, as "Seller," and
LipidViro Tech, Inc., a privately-held Utah corporation ("LipidViro"), as
"Buyer."  Pursuant to the terms of the Agreement, LipidViro acquired 5,000,000
shares of the Registrant's common stock or approximately 96% of its
outstanding voting  securities.  See the 8-K Current Report of the Registrant
dated June 24, 2003, which was previously filed with the Securities and
Exchange Commission on June 27, 2003, and which is incorporated herein by
reference.  See Item 7.

          The Registrant and LipidViro entered into an Agreement and Plan of
Reorganization (the "Reorganization Agreement"), a copy of which was attached
to the initial 8-K Current Report filed with the Securities and Exchange
Commission on September 9, 2003, and which is incorporated by reference, by
which LipidViro was to be acquired as a wholly-owned subsidiary of the
Registrant.  See Item 7.

          On August 19, 2003, LipidViro filed a Petition for Fairness Hearing
and a Motion for Expedited Hearing in the Third Judicial District Court in and
for Salt Lake County, State of Utah, respecting the Reorganization Agreement,
copies of which were also attached to the initial 8-K Current Report filed
with the Securities and Exchange Commission on September 9, 2003, and which
are also incorporated by reference.  The Petition for Fairness Hearing was
filed because of the 95% ownership of the Registrant by LipidViro and the fact
that following the closing of the Agreement with North Beck, the directors and
executive officers of LipidViro had been designated to serve as directors and
executive officers of the Registrant too.  See Item 7.  The Fairness Hearing
was requested in order for LipidViro's shareholders to receive the
contemplated issuance of securities under the Reorganization Agreement in
accordance with United States and Utah securities laws, and pursuant to the
exemption from registration provided in Section 3(a)(10) of the Securities Act
of 1933, as amended ("the Securities Act").  The Fairness Hearing was held on
September 8, 2003, and the Court took LipidViro's Petition under advisement,
after hearing oral argument, with the Court eventually deferring to the Utah
Division of Securities to conduct the Fairness Hearing, based upon the recent
adoption of an amendment to Section 61-1-11.1 of the Utah Uniform Securities
Act that granted the Utah Division of Securities authority to conduct such
hearings.  With (i) the Registrant being a Nevada corporation, (ii) there
being some question as to whether the Registrant or LipidViro should petition
for the Fairness Hearing and (iii) the Utah Division of Securities having not
formally adopted rules and regulations to implement such hearings, the
Registrant filed another Petition for Fairness Hearing in the Fourth Judicial
District Court of the State of Nevada, in and for the County of Elko, for a
Fairness Hearing on the Reorganization Agreement.

          The principal terms of the Reorganization Agreement were:

     1.   The LipidViro shareholders would deliver all of the LipidViro
securities held by LipidViro shareholders which shares and warrants shall
represented all of the issued and outstanding shares of LipidViro common stock
and "A" and "B" warrants, and the Registrant agreed to acquire such securities
in exchange for an aggregate of 9,818,750 shares of the Registrant's common
stock, par value $0.001 per share, for the LipidViro common stock, and
1,915,000 "A" warrants and 1,915,000 "B" like warrants of the Registrant for
the LipidViro warrants.

     2.   At the closing, the 5,000,000 shares of common stock of the
Registrant acquired by LipidViro from North Beck would be cancelled.

     3.   After giving effect to the Reorganization Agreement, the Registrant
would own all the issued and outstanding shares of LipidViro, and LipidViro
will be a wholly-owned subsidiary of the Registrant, operating under the name
"LipidViro Tech, Inc." or such other name selected by the shareholders and
management of LipidViro.

          On January 12, 2004, the Nevada Court conducted a Fairness Hearing
and found that the terms and provisions of the Reorganization Agreement and
the issuance and exchange of the securities of the Registrant and LipidViro
contemplated thereunder were fair to the Registrant's shareholders, based upon
the Registrant's acceptance of the terms of the Reorganization Agreement and
the information concerning the business and finances of the Registrant and
LipidViro, all of which was proffered to the Court by the Registrant's legal
counsel.

          Copies of this Petition for Fairness Hearing and the Court's Order
Granting Petition of Fairness were attached to the 8-KA Current Report dated
August 19, 2004, filed with the Securities and Exchange Commission on March
26, 2004, and are incorporated herein by reference.  See Item 7.

Plan of Operation.
------------------

     We are a development-stage biotechnology company, conducting research
focused on developing drug and biological products to treat infectious
pathogens and disease in which lipids or fat components play a key role.  We
have developed a technology based on a process that utilizes our lipid-
targeting investigational compound LVT3.  LVT3 is produced and delivered to
target pathogens by our proprietary drug production and delivery equipment. We
believe LVT3 and our proprietary process targets the lipids of certain
pathogens rendering them non-infectious.  Utilizing our proprietary process
and LVT3, we have commenced pre-clinical product development research designed
to:  (i) demonstrate the capacity of our technology to inactivate pathogens;
(ii) evaluate the toxicity and potential safety of our process; and (iii)
identify potential products for further development.

     Products we are currently evaluating for development include,
therapeutic treatments for diseases caused by infectious pathogens,
therapeutic treatments for lipid associated diseases and viral free
biologics.  We believe our unique lipid targeting technology has the potential
for inactivating or destroying a range of infectious and lipid rich pathogens,
including, the virus that cause SARS, West Nile, Asian Bird Flu, AIDS,
hepatitis B and C.  Many of the diseases caused by these viruses have
ineffective or poor treatment options.

     Our primary activities since incorporation have been developing drug
production and delivery equipment and conducting research to evaluate and
identify potential drug and biological products utilizing our proprietary
lipid targeting technology.  In addition, we have been performing business,
strategic and financial planning and raising capital.  We currently have no
approved, saleable products or services and we are accordingly, considered to
be a biotechnology company in the development stage.  During the first half of
2004, we funded operations and research from monies advanced from a
shareholder of the company.  We continue to seek long term financing to
support our research and operational activities.

Pre-Clinical Laboratory Research, Product Development.
------------------------------------------------------

          Our pre-clinical, product development research is designed to
evaluate our proprietary technology and process to inactivate various
pathogens including viruses, bacteria and prions.  The purpose of this
research is to evaluate efficacy, toxicity and the ability to deliver LVT3 to
a target pathogen.   Where appropriate, research results will be submitted for
peer review publication. Our pre-clinical product development research is
currently in progress.

          We utilize the results of our pre-clinical research studies to
identify potential products.  Each potential product is ranked for development
priority based on our assessment of the product's prospects for commercial
success. Our evaluation includes studying the efficacy and toxicity of LVT3
in-vitro, the time, expense and anticipated regulatory hurdles likely required
to reach commercialization, and, competition in that product category.

          Early research suggests our proprietary technology and process
possess a capacity to inactivate viruses.  While our research is preliminary
and incomplete, and will require additional research to verify, it does
suggests the potential for multiple products that we believe are worthy of
further investigation.   Product categories we are evaluating include: (i)
processing biologicals for pathogen removal and purification; (ii) developing
therapeutics to treat serious infectious diseases; and, (iii) developing
therapeutics for treating lipid associated diseases.

Equipment Development and Pre-Clinical Research.
------------------------------------------------

          During the first fiscal quarter of 2004, we designed, engineered and
constructed the first generation of our proprietary drug manufacturing
equipment utilized in producing our investigational compound, LVT3.  We also
engineered and constructed the first ("GEN-1") and second generation ("GEN-2")
of our proprietary LVT3 drug delivery systems utilized in our Viral
Inactivation Platform.   After constructing and testing the equipment, we
commenced pre-clinical research of LVT3 with out GEN-2 technology.

          On March 29, 2004, we released pre-clinical research results of
studies that utilized LVT3 and our GEN-2 technology.  The results demonstrated
substantial inactivation of four different infectious viruses, including: a
DNA and a RNA virus, both with simple lipid envelopes; a DNA virus with a
complex lipid envelope; and, a small, non-enveloped virus.  The research was
sponsored by us and conducted by an independent laboratory. The studies were
performed in a variety of biological media chosen to represent potential
candidates for commercial products.  We are encouraged by these results, as a
demonstration of antiviral efficacy in four differently structured viruses
suggests a broad spectrum antiviral capacity, with the ability to inactivate
multiple families of viruses structured similarly to those studied.  See the
8-K Current Report dated and filed May 10, 2004, with the Securities and
Exchange Commission, which is incorporated herein by reference.  See Item 7.

     Also during the first quarter, we utilized our observations from
performing hundreds of studies with the GEN-1 and GEN-2 systems to further
refine our drug delivery technology, which focuses on maximizing the efficacy
of LVT3.  As a result of these efforts, late in the first quarter, we
completed engineering and construction of our third generation ("GEN-3") drug
delivery system.

     During the second fiscal quarter of 2004, we initiated performance
assessment of the newly constructed GEN-3 system, performed studies to further
evaluate our Viral Inactivation Platform, initiated a series of toxicity
studies and expanded the scope of our research by initiating prion research
and developing our Cardiovascular Platform.

     GEN-3 Evaluation.  During the quarter, we initiated preliminary studies
designed to evaluate the performance of the newly constructed GEN-3 drug
delivery technology.  The GEN-3 technology will be used in our Viral
Inactivation Platform and our Cardiovascular Disease Platform.  The studies
were designed using infectious virus prepared in artificially contaminated
commercial bovine growth serum preparations, and compared efficiency and
performance to our earlier GEN-2 technology.  On May 10, 2004, we announced
preliminary results of this research.  The studies were conducted on an RNA-
based, nucleo-enveloped rhabdovirus, and demonstrated substantial inactivation
of the measurable virus in less than half the time required by the older GEN-2
technology.  In addition, the studies demonstrated the new GEN-3 system
required less than half the dosage of LVT3 required by the earlier GEN-2
system to achieve similar viral inactivation.  These improvements are very
encouraging for our Viral Inactivation Platform, but also translate directly
to all of our disease Platforms, which will also utilize the GEN-3 drug
delivery technology.

     Toxicity Evaluation.  Our toxicity studies are designed to evaluate
various complex components of biological systems treated with LVT3 and the
GEN-3 system.  We initiated a variety of toxicity studies during the second
quarter.  These studies are in progress and are designed to evaluate toxicity
while also identifying dosing levels which provide efficacy while maintaining
sufficient biological integrity.

     Prion Research.  Due to tighter regulatory controls of infectious
biologics as a result of terrorism, the process of performing research on
various infectious agents now requires additional regulatory approval.  This
is now the case with prion research.  During the quarter, our laboratory
facilities took part in, and passed, USDA and state health inspections.  In
addition, the laboratory applied for and received USDA licensing to purchase
and transport infectious prion material.   By clearing these hurdles, the
laboratory is now approved to conduct prion research utilizing LVT3 and our
GEN-3 system. Due to the complexity and the required incubation period in many
of the prion studies, we expect to begin this research during the third
quarter, but may not achieve measurable results until the fourth fiscal
quarter.

     Cardiovascular Platform.  During the quarter, we began development and
design of pre-clinical studies associated with our Cardiovascular Platform.
Our objective is to design and initiate pre-clinical studies during the fourth
fiscal quarter that target cardiovascular disease. These studies will evaluate
our ability to effect lipids, cholesterols and triglycerides in a way that may
positively impact arteriosclerosis and effect arterial plaque reduction.

     We have filed for patent protection covering our LVT3 drug production
and GEN-1, GEN-2 and GEN-3 drug delivery devices, and for proprietary
applications utilized by our process.

ITEM 3 CONTROLS AND PROCEDURES

     As of the end of the period covered by this Quarterly Report, we carried
out an evaluation, under the supervision and with the participation of our
President, of the effectiveness of our disclosure controls and procedures.
Based on this evaluation, our President concluded that our disclosure controls
and procedures are effective in timely alerting them to material information
required to be included in our periodic Securities and Exchange Commission
reports.  It should be noted that the design of any system of controls is
based in part upon certain assumptions about the likelihood of future events,
and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions, regardless of how remote.
In addition, we reviewed our internal controls over financial reporting, and
there have been no changes in our internal controls or in other factors in the
last fiscal quarter that has materially affected or is reasonably likely to
materially affect our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
          ------------------

          None; not applicable.

Item 2.   Changes in Securities and Small Business Issuer Purchases of Equity
Securities.
-----------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
          --------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
          ----------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
          ------------------

          None; not applicable

Item 6.   Exhibits and Reports on Form 8-K.
          ---------------------------------

          (a)  Exhibits.

          31 302 Certification of Kenneth P. Hamik

          32 906 Certification

          (b)  Reports on Form 8-K.

          8-K/A Report dated August 19, 2003, and filed March 26, 2004,
          regarding Certificate of Amendment to the Articles of
          Incorporation, Bylaws, Petition for Fairness Hearing, Agreement
          and Plan of Reorganization, Motion for Expedited Hearing, Petition
          for Fairness Hearing in the State of Nevada, Nevada Court Order
          Granting Petition of Fairness.

          8-K Current Report dated March 29, 2004, and filed March 30, 2004,
          regarding a press release.

          8-K Current Report dated and filed May 10, 2004, regarding a press
          release.

                               SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                     LIPIDVIRO TECH, INC.


Date: 8/13/2004                    By/s/Kenneth P. Hamik
      --------------                 -------------------
                                     Kenneth P. Hamik
                                     President, CFO and Director